ASH 2024: vídeos e entrevistas
47 vídeos do ASH 2024 publicados por ASCO Podcasts, ASH, OncLive, Oncology Brothers, Targeted Oncology, ecancer. Atualizado em 20/11/2026.
ASH News TV 2024: ASH Annual Meeting Monday RecapASH · 21/07/2025 · 22:56
ASH News TV 2024: ASH Annual Meeting 2024 Sunday RecapASH · 21/07/2025 · 20:56
ASH News TV 2024: ASH Annual Meeting Plenary Scientific SessionASH · 21/07/2025 · 4:39
ASH News TV 2024: ASH 2024 Annual Meeting Saturday RecapASH · 21/07/2025 · 15:59
ASH News TV 2024: Welcome to 2024 ASH Annual MeetingASH · 21/07/2025 · 4:59
ASH News TV 2024: ASH 2024 Annual Meeting Friday RecapASH · 21/07/2025 · 18:11
High-fibre dietary intervention in plasma cell disorders improves biomarkers of disease, may del...ecancer · 06/02/2025 · 6:20 · apoio da indústria
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatme...ecancer · 06/02/2025 · 5:26 · apoio da indústria
Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy...ecancer · 06/02/2025 · 5:46 · apoio da indústria
Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus p...ecancer · 06/02/2025 · 4:04 · apoio da indústria
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-l...ecancer · 06/02/2025 · 2:57 · apoio da indústria
Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving tec...ecancer · 06/02/2025 · 5:39 · apoio da indústria
Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in R...ecancer · 06/02/2025 · 5:41 · apoio da indústria
Impact of MRD on progression-free survival in MM patients treated with isatuximab, lenalidomide,...ecancer · 06/02/2025 · 4:07 · apoio da indústria
Demographics, characteristics, survival and outcomes in older, untreated, AML with NPM1 mutation...ecancer · 06/02/2025 · 4:23 · apoio da indústria
IDH2 mutation associated with favourable outcome in older adults with newly diagnosed ALL treate...ecancer · 06/02/2025 · 2:54 · apoio da indústria
Outcomes and survival in newly diagnosed, older, AML patients from the Beat AML Master Trial in ...ecancer · 06/02/2025 · 3:37 · apoio da indústria
Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in r/r fo...ecancer · 06/02/2025 · 2:17 · apoio da indústria
Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standar...ecancer · 06/02/2025 · 4:32 · apoio da indústria
Teclistamab-based induction regimens demonstrate manageable safety and efficacy in patients with...ecancer · 06/02/2025 · 6:07 · apoio da indústria
Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapyecancer · 06/02/2025 · 3:53 · apoio da indústria
Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-ce...ecancer · 06/02/2025 · 3:35 · apoio da indústria
Analysis of pre-treatment biomarkers associated with toxicity and durable responses in idecabtag...ecancer · 06/02/2025 · 4:41 · apoio da indústria
Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem c...ecancer · 06/02/2025 · 2:58 · apoio da indústria
Pembrrolizumab after chemotherapy demonstrates promising activity and manageable safety in patie...ecancer · 06/02/2025 · 4:11 · apoio da indústria
Dr Burke Pinpoints Top Trends from ASH 2024Targeted Oncology · 03/02/2025 · 9:45 · apoio da indústria
Dr Ghia on a Pooled Analysis of OS Outcomes With Ibrutinib Plus Venetoclax in CLLOncLive · 13/01/2025 · 1:22 · apoio da indústria
Multiple Myeloma ASH 2024 Highlights with Dr. Robert OrlowskiOncology Brothers · 07/01/2025 · 22:19 · apoio da indústria
ASH 2024 CLL Highlights - SEQUOIA, AMPLIFY, CELESTIALOncology Brothers · 26/12/2024 · 22:00 · apoio da indústria
David John Lewis, MD: Ibrutinib and Rituximab in Older Patients with Mantle Cell LymphomaASH · 20/12/2024 · 12:08
Rachael Grace, MD, & Michele Lambert, MD: Immune Disorders and Mortality in Pediatric AIHAASH · 20/12/2024 · 13:24
Rachel E. Rau, MD & Sumit Gupta, MD, PhD: Blinatumomab in Pediatric B-ALLASH · 20/12/2024 · 18:38
Meletios-Thanos Dimopoulos, MD: Daratumumab Vs. Active Monitoring in High-Risk Smoldering MyelomaASH · 20/12/2024 · 16:08
Anne de Vaan, MD: Postpartum Hemorrhage in Hemophilia A and B CarriersASH · 20/12/2024 · 11:48
Leukemia ASH 2024 Highlights - Menin Inhibitors, CPX 351 vs 7+3, Venetoclax Based RegimensOncology Brothers · 19/12/2024 · 18:00 · apoio da indústria
Jordan Schaefer, MD, MSc: Treatment vs. Prophylaxis for Extended VTE ManagementASH · 12/12/2024 · 10:43
Wallace H. Coulter Award for Lifetime Achievement in Hematology – 2024 Acceptance SpeechASH · 10/12/2024 · 5:20
ASH Mentor Award – 2024 Acceptance SpeechASH · 10/12/2024 · 6:19
Top Anticipations for ASH 2024: Oncologists Share Key Highlights to WatchTargeted Oncology · 06/12/2024 · 3:38 · apoio da indústria
ASH in a Flash - Artificial Intelligence in Hematology: From Generative AI to Ethics & ApplicationsASH · 26/11/2024 · 1:11
ASH in a Flash - Therapeutic Gene Editing of Stem Cells in Classical & Malignant HematologyASH · 26/11/2024 · 1:02
ASH in a Flash - Molecular Characterization of Lymphomas in Children, Adolescents & Young AdultsASH · 26/11/2024 · 1:14
ASH in a Flash - The Fuel & Physiology of Regeneration - Dr. Hanna MikkolaASH · 26/11/2024 · 1:12
ASH in a Flash - Race and Ancestry in Precision Medicine - Dr. Sant-Rayn PasrichaASH · 22/11/2024 · 1:04
ASH Clinical News: November 2024 From the Desk Of...ASH · 21/10/2024 · 2:27
66th ASH Annual Meeting and Exposition | San Diego, CAASH · 26/06/2024 · 1:12
Advances in CAR T-cell Therapy for LymphomaASCO Podcasts · 08/04/2024 · 21:49